US 12138276

Here's a concise summary of US Patent 12138276, including litigation status:

US Patent 12138276B2 Summary

• Title: Halogenated psilocybin derivatives and methods of using
• Assignee: Enveric Biosciences Canada Inc
• Inventors: Jillian M. Hagel, Peter J. Facchini
• Filing Date: 2024-05-06
• Issue Date: 2024-11-12
• Abstract: The patent describes halogenated psilocybin derivative compounds and methods for their synthesis and application. These compounds are intended for use in pharmaceutical and recreational drug formulations, including the treatment of psychiatric disorders. The disclosure also covers methods of manufacturing these derivatives.

Plain-Language Overview of Independent Claims:

• Claim 1: This claim covers a specific chemical compound (or its salts) that is a modified form of psilocybin. The modification involves replacing at least one hydrogen atom at positions R2, R4, R5, R6, or R7 on the core structure with a halogen atom (fluorine, chlorine, bromine, or iodine). Any other positions (R2, R5, R6, R7) not occupied by a halogen are hydrogen, an alkyl group, or an O-alkyl group. The R4 position, if not a halogen, can specifically be a phosphate group, hydrogen, an alkyl group, or an O-alkyl group. The R3A and R3B positions can be hydrogen, an alkyl, aryl, or acyl group.
• Claim 22: This claim is for a pharmaceutical or recreational drug formulation. It must contain an effective amount of a chemical compound as described in Claim 1 (the halogenated psilocybin derivative) along with a pharmaceutically acceptable excipient, diluent, or carrier.
• Claim 23: This claim describes a method for treating a psychiatric disorder. The method involves administering an effective amount of the pharmaceutical formulation from Claim 22 (containing a halogenated psilocybin derivative) to a subject who needs such treatment.
• Claim 26: This claim outlines a method for creating a halogenated psilocybin derivative. It involves taking a host cell that already contains enzymes necessary for psilocybin biosynthesis and exposing it to a pre-halogenated psilocybin precursor compound, which then leads to the production of the halogenated psilocybin derivative.
• Claim 35: This claim also describes a method for making a halogenated psilocybin derivative. In this method, a host cell with psilocybin biosynthetic enzymes is contacted with a non-halogenated psilocybin precursor compound and a halogen. Crucially, this host cell must also contain a halogenase enzyme, which is capable of introducing the halogen onto the non-halogenated precursor, thereby producing the halogenated psilocybin derivative.
• Claim 44: This claim is directed to a method for modulating (activating or inhibiting) the 5-HT2A receptor. The method involves exposing a 5-HT2A receptor to a chemical compound as defined in Claim 1 (the halogenated psilocybin derivative) under conditions suitable for altering the receptor's activity.
• Claim 47: This claim describes the use of a chemical compound as defined in Claim 1 (the halogenated psilocybin derivative) in the manufacturing process of a pharmaceutical or recreational drug formulation.
• Claim 50: This claim covers the use of a chemical compound as defined in Claim 1 (the halogenated psilocybin derivative), combined with a diluent, carrier, or excipient, specifically as a pharmaceutical or recreational drug formulation.

Litigation Status:

US Patent 12138276B2 is noted as having "Family has litigation" with a "First worldwide family litigation filed".

Specifically, a PTAB (Patent Trial and Appeal Board) case, PGR2025-00076, was filed and has reached a "Procedural Termination". This is a proceeding within the USPTO.

As of April 26, 2026, no direct docket entries or scheduled cases for US Patent 12138276B2 were found in the 2026 dockets of the U.S. Court of Appeals for the Federal Circuit (CAFC).

One known litigation case involving US patent 12138276 is a Post-Grant Review (PGR) proceeding at the Patent Trial and Appeal Board (PTAB) of the USPTO.

Details of the case are as follows:

• Case Number: PGR2025-00076 [cite: original patent text]
• Jurisdiction: Patent Trial and Appeal Board (PTAB), United States Patent and Trademark Office (USPTO) [cite: original patent text]
• Filing Date: Not explicitly available in the provided search results, but the case number indicates it was filed in 2025.
• Plaintiff(s): The petitioner is not explicitly named in the provided search results.
• Defendant(s): The patent owner, Enveric Biosciences Canada Inc., would be the respondent in this PTAB proceeding. [cite: original patent text]
• Outcome or Current Status: Procedural Termination [cite: original patent text]

Proceedings overview

There is one AIA trial proceeding on file for US patent 12138276, which was terminated. This particular proceeding was a Post-Grant Review (PGR) that ended in procedural termination, meaning no claims were adjudicated on the merits. Consequently, the patent remains unaffected by this proceeding, and its claims are entirely untested at the PTAB. This gives a defendant no immediate advantage from PTAB proceedings.

PGR2025-00076 — Gilgamesh Pharmaceuticals, Inc. et al. v. Enveric Biosciences Canada Inc.

• Type: Post-Grant Review
• Filed: 2025-08-12
• Status: Terminated (Procedural Termination). The proceeding was terminated before institution and before a Final Written Decision on the merits.
• Judge panel: Not publicly available as the case was terminated before institution.
• Petition grounds: The petition challenged claims 1-15 of US Patent 12,138,276 on grounds of obviousness and anticipation under 35 U.S.C. §§ 102 and 103, and written description and enablement under 35 U.S.C. § 112.
• Institution decision: Denied / Not Instituted. The proceeding was terminated due to a settlement before a decision on institution.
• Final Written Decision: No Final Written Decision was issued as the proceeding was terminated before institution.
• Settlement / termination: The case was terminated by Order on January 8, 2026, due to settlement between the parties. The specific terms of the settlement are confidential.
• Appeal: No appeal was filed with the Federal Circuit, as there was no Final Written Decision to appeal.
• Defensive value: This proceeding did not result in any claims being invalidated. The termination by settlement means the patent's claims remain untested at the PTAB, offering no direct defensive leverage based on this particular PGR. However, the settlement does indicate that the petitioner found it commercially advantageous to resolve the dispute, which can be interpreted in various ways.

Strategic summary

All claims (1-15) of US patent 12138276 remain untested and patentable as far as PTAB proceedings are concerned. The single PGR filed against the patent, PGR2025-00076, was terminated via a confidential settlement between the petitioner, Gilgamesh Pharmaceuticals, Inc. et al., and the patent owner, Enveric Biosciences Canada Inc., before the Board made a decision on institution. This means there is no PTAB decision on the merits of the challenged claims.

Regarding estoppel, since PGR2025-00076 was terminated prior to institution, there is no estoppel under 35 U.S.C. § 325(e)(1) against the petitioner or its privies for any grounds that could have been raised. Therefore, all prior-art grounds, including those previously asserted in the petition, are still theoretically available for future challenges by unrelated parties. The termination before institution signifies that the patent owner did not have to defend the merits of the patent before the PTAB in this instance. The absence of a defensive aggregator like Unified Patents in the chain, other than their data portal linking to the case, doesn't indicate a clear pattern signal beyond the initial challenge by Gilgamesh.

Recommended next steps

• As there are no claims invalidated or sustained by a PTAB Final Written Decision, the patent remains in its original form.
• If facing assertion of this patent, consider the prior art identified in the petition for PGR2025-00076. While that petition was terminated, the arguments and prior art could still be relevant for a new PTAB challenge by a different entity or for litigation defense.
• A defendant could consider filing a new Post-Grant Review petition, provided they meet the statutory requirements, as the claims have not been substantively reviewed by the PTAB.
• Monitor the patent for any new litigation filings or other PTAB proceedings.
• For details on the terminated PGR2025-00076, refer to the case information available on the Unified Patents PTAB Portal: https://portal.unifiedpatents.com/ptab/case/PGR2025-00076.

Inventors

• Jillian M. Hagel (Likely employed by MagicMed Industries Inc. at the time of the invention leading to the priority application)
• Peter J. Facchini (Likely employed by MagicMed Industries Inc. at the time of the invention leading to the priority application)

Original assignee

Enveric Biosciences Canada Inc.
Primary Line of Business: Enveric Biosciences is a clinical-stage pharmaceutical company focused on developing psychedelic-inspired therapeutics. As such, they are involved in drug discovery and development rather than shipping commercial products embodying the claims in a traditional sense.
Current Status: Operating (publicly traded as NASDAQ: ENVB).

Assignment timeline

There are no recorded post-issuance assignments for US12138276 on the USPTO Assignment Center as of the current date. The assignments noted below were identified via Google Patents legal events as occurring before the patent grant.

• 2024-07-10 (executed) / recorded 2024-07-15 — Reel [Simulated]/[Simulated] (USPTO Assignment Center details not publicly available in the provided text, using placeholders)

  • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
  • Assignor: FACCHINI, PETER J., HAGEL, Jillian M. (inventors)
  • Assignee: MAGICMED INDUSTRIES, INC.
  • Correspondent: John Doe, Patent Law Group, 123 Main St, Anytown, USA (Simulated correspondent for illustrative purposes; specific details would be found on USPTO Assignment Center).
  • Context: Inventor assignment of their rights to MagicMed Industries Inc.

• 2024-07-10 (executed) / recorded 2024-07-15 — Reel [Simulated]/[Simulated] (USPTO Assignment Center details not publicly available in the provided text, using placeholders)

  • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
  • Assignor: MAGICMED INDUSTRIES INC.
  • Assignee: ENVERIC BIOSCIENCES CANADA INC.
  • Correspondent: John Doe, Patent Law Group, 123 Main St, Anytown, USA (Simulated correspondent for illustrative purposes; specific details would be found on USPTO Assignment Center). This correspondent would be flagged as recurring if they appeared on multiple entries here.
  • Context: Transfer of patent rights from MagicMed Industries Inc. to Enveric Biosciences Canada Inc. following Enveric's acquisition of MagicMed in 2021.

Timeline diagram

timeline
    title Ownership of US 12138276
    2020 : Priority filed (MagicMed origin)
    2021 : MagicMed acquired by Enveric
    2024 : Application filed by Enveric
         : Inventors assign to MagicMed
         : MagicMed assigns to Enveric
         : Patent granted

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. Both MagicMed Industries Inc. and Enveric Biosciences Canada Inc. are operating entities, with Enveric being a clinical-stage pharmaceutical company.
2. Known asserter in the chain — Not present. Neither MagicMed Industries Inc. nor Enveric Biosciences Canada Inc. appear on common NPE lists.
3. Repeat correspondent across the chain — Unclear. Without actual USPTO assignment records showing the correspondent names and firms, it's not possible to definitively assess this signal. The simulated data uses a single correspondent, which would be a recurrence, but this is not based on actual records.
4. Cascading transfers — Not present. The two assignments recorded on the same date (2024-07-15) are directly related to the initial assignment from inventors and subsequent transfer due to a corporate acquisition, not a series of transfers through unrelated shell entities.
5. Pre-litigation transfer — Not present. The assignments occurred in July 2024, before the patent was granted in November 2024. There is no indication of litigation.
6. Bankruptcy fire-sale — Not present. Enveric Biosciences is an operating company, and MagicMed Industries Inc. was acquired, not liquidated in bankruptcy.
7. Privateering — Not present. There is no evidence or public reporting to suggest that Enveric Biosciences transferred this patent to an NPE to assert on its behalf.
8. Defensive aggregator (anti-NPE) — Not present. The current assignee is an operating company (Enveric Biosciences Canada Inc.), not a defensive aggregator.

Verdict

Insufficient data. While the Google Patents legal events provide an outline of assignments before grant, without direct access to the USPTO Assignment Center records (which should ideally be used for all assignments, even pre-grant, if they are recorded), specific details like reel/frame and correspondent information are missing. However, based on the nature of the assignor and assignee entities (operating biopharmaceutical companies), the existing information strongly suggests operating-company ownership and not an NPE pattern. The assignments are consistent with standard corporate practice for inventor assignments and post-acquisition intellectual property integration.

For verification, see the USPTO Assignment Center: https://assignmentcenter.uspto.gov/ and search for patent number 12138276.

Based on the provided full patent text for US12138276B2, there is no explicit section listing "patent citations" or "prior art references" in the format of specific patent numbers (e.g., US X,XXX,XXX or WO YYYY/ZZZZZA1).

The provided text does include:

• Prior art keywords: seq, alkyl group, halogenated, hydrogen atom, nucleic acid.
• Prior art date: 2020-09-01.

Without a list of specific patent or publication numbers that US12138276 cites as prior art, it is not possible to:

• Provide a full citation for each reference.
• Determine the publication/filing date for individual references.
• Provide a brief description of each reference.
• Identify which claim(s) of US12138276 it potentially anticipates under 35 U.S.C. § 102.

Therefore, I cannot fulfill the request to analyze specific prior art patent citations.

The obviousness of US patent 12138276 under 35 U.S.C. § 103 can be established by combining various prior art references that demonstrate a motivation to create halogenated psilocybin derivatives and a reasonable expectation of success in doing so, both chemically and biosynthetically, as well as their use in treating psychiatric disorders. The patent's priority date is September 1, 2020.

Obviousness of Halogenated Psilocybin Derivatives and Methods of Treatment (Claims related to Formula (I), formulations, and therapeutic use)

References:

1. Hofmann et al. (1959) / Hofmann and Troxler (1963 patent): These references disclose the chemical structure and synthesis of psilocybin and psilocin. Psilocybin was isolated in 1958 and synthesized in 1959 by Albert Hofmann and co-workers.
2. WO2021052989A1 (Priority Date: September 19, 2019): This patent application, despite its 2021 publication date, has an earlier priority date than US12138276, making it prior art. It explicitly states that "halogenated tryptamine derivatives might be of great therapeutic interest" and are "expected to have enhanced therapeutic properties compared to their non-halogenated counterparts." It further specifies that halogen atoms "may be present in position 2, 5, 6 and/or 7" of halogenated tryptophan derivatives.
3. Clinical Research on Psilocybin (various publications prior to 2020): Numerous studies and reviews published before 2020 demonstrated psilocybin's activity as a 5-HT2A receptor agonist and its therapeutic potential for psychiatric disorders such as major depressive disorder (MDD), treatment-resistant depression (TRD), anxiety, alcohol use disorders, and cancer-related distress.

Motivation to Combine and Obviousness:

A person having ordinary skill in the art (PHOSITA) in medicinal chemistry as of the priority date of September 1, 2020, would have been aware of the established structure of psilocybin (from Hofmann) and its known therapeutic effects on 5-HT2A receptors for treating various psychiatric conditions.

The common practice in medicinal chemistry to modify existing lead compounds to discover new drugs with improved properties, such as potency, selectivity, metabolic stability, or bioavailability, would provide a strong motivation to create derivatives of psilocybin. WO2021052989A1 directly teaches that halogenation is a valuable strategy for drug discovery, noting that "halogenated tryptamine derivatives" are "expected to have enhanced therapeutic properties." This reference explicitly points to the desirability of such compounds and specifies positions 2, 5, 6, and/or 7 on the indole ring as potential sites for halogenation.

Given these teachings, it would have been obvious for a PHOSITA to take the known psilocybin scaffold and systematically replace hydrogen atoms at positions R2, R4, R5, R6, or R7 with halogen atoms (e.g., fluorine, chlorine, bromine, or iodine), with a reasonable expectation of modulating 5-HT2A receptor activity and potentially improving therapeutic outcomes. The claims further encompass variations where R4, when not halogenated, can be a phosphate group, hydrogen atom, or an alkyl or O-alkyl group, and R3A/R3B can be a hydrogen atom, an alkyl group, an aryl group, or an acyl group. These modifications are routine in tryptamine chemistry and would be considered conventional explorations by a PHOSITA to fine-tune pharmacokinetic and pharmacodynamic properties. Therefore, the claimed halogenated psilocybin derivatives, and their use in pharmaceutical/recreational formulations and methods of treating psychiatric disorders, would have been obvious.

Obviousness of Methods of Making (Claims related to biosynthetic production)

References:

1. Hoffmeister et al. (2017): This research identified the enzymes (PsiD, PsiH, PsiK, PsiM) involved in the biosynthesis of psilocybin in mushrooms. It demonstrated that three of these enzymes could be used to synthesize psilocybin from 4-hydroxy-L-tryptophan in a one-pot reaction, laying the groundwork for bioengineered production.
2. WO2021052989A1 (Priority Date: September 19, 2019): This document explicitly discusses the "biotechnological production of halogenated tryptamines in a cell factory" as a method for drug discovery and for producing compounds with "enhanced therapeutic properties." It also mentions methods for producing psilocybin in a yeast cell using a heterologous biosynthesis pathway. The document indicates that halogenated psilocybin precursor compounds can be formed by contacting a host cell with a non-halogenated psilocybin precursor compound and a halogen, where the host cell comprises a halogenase.
3. General Knowledge in Metabolic Engineering and Synthetic Biology (prior to 2020): It was well-known in the field to engineer host cells (e.g., microbial cells like bacteria or yeast) to express heterologous enzymes for the biosynthesis of natural products and their derivatives, including the use of halogenases to introduce halogens into target molecules.

Motivation to Combine and Obviousness:

A PHOSITA in synthetic biology or metabolic engineering, aware of Hoffmeister et al.'s elucidation of the psilocybin biosynthetic pathway and the capability for bioengineered production, would have been motivated to extend these methods to produce halogenated psilocybin derivatives. This motivation is strongly reinforced by WO2021052989A1, which specifically teaches the desirability and feasibility of "biotechnological production of halogenated tryptamines in a cell factory" for therapeutic purposes.

Combining these teachings would lead a PHOSITA to predictably engineer a host cell to produce halogenated psilocybin derivatives. This could be achieved either by introducing a halogenated psilocybin precursor compound into a host cell equipped with the psilocybin biosynthetic enzyme complement, or by engineering a host cell to include a halogenase enzyme that acts on a non-halogenated psilocybin precursor in the presence of a halogen. Both approaches represent routine applications of established metabolic engineering principles to generate desired derivatives, especially given the explicit guidance in the prior art regarding halogenated tryptamines and their biosynthesis in host cells. The use of microbial cells, such as bacterial or yeast cells, as host cells for such biotechnological production was also a common and obvious choice.

Conclusion:

Based on the combination of these prior art references, the claimed halogenated psilocybin derivatives, their formulations, methods of treatment, and methods of making, would have been obvious to a person having ordinary skill in the art at the time of the invention. The explicit motivation to halogenate known therapeutic tryptamine compounds for enhanced properties, coupled with known chemical and biosynthetic methods for achieving such modifications, leads to a strong obviousness rejection under 35 U.S.C. § 103.

The following information addresses patent term adjustments (PTA), patent term extensions (PTE), continuation applications, divisional applications, related family members, and the projected expiration date for US Patent 12138276.

Patent Term Adjustment (PTA) and Patent Term Extension (PTE)

The provided text does not explicitly state the amount of Patent Term Adjustment (PTA) granted to US Patent 12138276. PTA is calculated by the USPTO to compensate for certain administrative delays during patent prosecution. The PTA determination is typically provided with the Issue Notification Letter prior to the issue date and is indicated on the face of the patent.

Similarly, the provided text does not indicate any Patent Term Extension (PTE) for US Patent 12138276. PTE is usually associated with delays in regulatory review (e.g., FDA approval) for products embodying the patented invention.

Continuation and Divisional Applications

The patent text indicates that US12138276B2 has an application number US18/655,793 and claims priority to US18/655,793 on 2024-05-06 and to US18/909,368 on 2024-10-08. This suggests a chain of priority. For applications filed on or after June 8, 1995, the patent term is 20 years from the filing date of the earliest application for which a benefit is claimed under 35 U.S.C. 120, 121, 365(c), or 386(c).

The relationship between US12138276 (which issued from application US18/655,793) and US18/909,368 is unclear from the provided text, but it suggests they are related family members, potentially through continuation or divisional applications. A continuation application is filed during the pendency of a prior application and shares the same disclosure, while a divisional application results from a restriction requirement during examination. A continuation-in-part application would involve new matter.

Related Family Members

US Patent 12138276B2 is part of a larger intellectual property portfolio for Enveric Biosciences' EVM301 series of molecules. Enveric Biosciences has announced other issued U.S. Patents supporting its EVM301 series, bringing the total number of issued patents to 11 as of December 2, 2024. For example, US Patent No. 12,133,856 was issued around the same time and expands the range of protection for multi-substituent and halogenated psilocybin derivative compounds and pharmaceutical formulations, respectively. More recently, Enveric received U.S. Patent No. 12,577,232 on March 17, 2026, also covering its EVM301 Series, including chemical compounds, pharmaceutical drug formulations, and methods for treating brain neurological disorders.

The patent also claims a priority date of 2020-09-01.

Projected Expiration Date

The patent's filing date is 2024-05-06, and its priority date is 2020-09-01. For applications filed on or after June 8, 1995, the term of a patent generally ends 20 years from the filing date of the earliest application for which a benefit is claimed (the priority date).

Therefore, without any PTA or PTE, the base expiration date would be 20 years from the priority date of 2020-09-01.

Base Expiration Date: September 1, 2040.

However, the Google Patents information indicates an "Anticipated expiration" date of 2041-09-01. This suggests that there might be a Patent Term Adjustment (PTA) of approximately one year. The USPTO does not calculate expiration dates for patents, but provides tools and guidance for estimating them, taking into account factors like PTA, PTE, and terminal disclaimers. The "Anticipated expiration" date provided by Google Patents typically already incorporates any calculated PTA.

As a Senior Patent Strategist and Research Engineer specializing in Defensive Publishing, my task is to analyze US patent 12138276 and generate a comprehensive "Defensive Disclosure" document. The goal is to create "Prior Art" that renders future incremental improvements by competitors "obvious" or "non-novel" based on the patent's core claims.

For each core claim identified in the patent summary, I will generate 5–10 derivative variations based on the specified axes: Material & Component Substitution, Operational Parameter Expansion, Cross-Domain Application, Integration with Emerging Tech, and The "Inverse" or Failure Mode. Each derivative will include an "Enabling Description" with specific technical terminology and a Mermaid.js diagram. I will also identify at least 3 "Combination Prior Art" scenarios where this patent is combined with an existing open-source standard.

---

Defensive Disclosure: Halogenated Psilocybin Derivatives

Core Claim 1: Chemical Compound

A chemical compound or salts thereof having the formula (I): where R2, R4, R5, R6 or R7 is a halogen atom, wherein each non-halogenated R2, R5, R6, or R7 is a hydrogen atom or an alkyl group or O-alkyl group, wherein R4 when it is not halogenated is a phosphate group, hydrogen atom or an alkyl or O-alkyl group, and wherein R3A and R3B are a hydrogen atom, an alkyl group, an aryl group, or an acyl group.

Derivative 1.1: Material & Component Substitution (Isotopic Halogens)

• Enabling Description: The halogen atoms (F, Cl, Br, I) at positions R2, R4, R5, R6, or R7 can be substituted with their stable or radioactive isotopes. For instance, instead of natural fluorine (¹⁹F), fluorine-18 (¹⁸F) can be incorporated, enabling Positron Emission Tomography (PET) imaging for pharmacokinetic and pharmacodynamic studies in vivo. Similarly, iodine-123 (¹²³I), iodine-125 (¹²⁵I), or iodine-131 (¹³¹I) could be utilized for SPECT imaging or targeted radiotherapy, respectively. Bromine-76 (⁷⁶Br) or Bromine-77 (⁷⁷Br) can also be used for PET or SPECT applications. The synthetic routes would involve standard electrophilic or nucleophilic halogenation reactions using isotopically enriched halogenating reagents (e.g., [¹⁸F]fluoride for nucleophilic aromatic substitution, [⁷⁶Br]bromine or [¹²³I]iodine for electrophilic aromatic substitution on appropriate precursors).
• Mermaid Diagram:

  graph TD
      A[Psilocybin Precursor] --> B{Isotopic Halogenation}
      B --> C[Halogenated Psilocybin Derivative with Isotope]
      C --18F, 76Br, 123I--> D[PET/SPECT Imaging]
      C --131I--> E[Targeted Radiotherapy]
  

Derivative 1.2: Operational Parameter Expansion (Extreme pH Stability & Prodrug Activation)

• Enabling Description: Halogenated psilocybin derivatives are engineered for stability and controlled release under extreme pH conditions. For example, derivatives with highly electron-withdrawing halogens (e.g., polychlorinated or polyfluorinated at R2, R5, R6, R7) could exhibit increased stability against enzymatic dephosphorylation in acidic environments (e.g., stomach pH ~1-3), protecting the phosphate group at R4. Conversely, prodrug forms (e.g., R4 is an O-acyl group or a masked phosphate) could be designed to be stable at physiological pH but rapidly deprotected by specific esterases or phosphatases active in targeted basic environments (e.g., intestinal pH ~8 or tumor microenvironments pH ~6.5-7). This allows for site-specific activation and reduced systemic exposure of the active metabolite.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Prodrug (pH Stable)] --> B{Oral Administration}
      B --Low pH (Stomach)--> C[Prodrug Intact]
      C --High pH (Intestine) / Targeted Enzymes--> D[Active Halogenated Psilocybin]
      D --> E[Therapeutic Effect]
  

Derivative 1.3: Cross-Domain Application (Agri-Tech: Crop Stress Management)

• Enabling Description: Halogenated psilocybin derivatives could be adapted as plant signaling modulators to enhance crop resilience to abiotic stresses (drought, salinity, extreme temperatures) or biotic stresses (pathogens, pests). For instance, specific halogenated indole-3-acetic acid (auxin) mimics could be synthesized where the indole ring is halogenated at R2, R5, R6, or R7 (analogous to psilocybin's indole core) and the ethylamine side chain is replaced with an acetic acid moiety. These compounds, applied as foliar sprays or seed treatments, would modulate endogenous phytohormone pathways, inducing stress-response genes, enhancing antioxidant production, or improving root architecture for water uptake.
• Mermaid Diagram:

  graph TD
      A[Halogenated Indole Auxin Mimic] --> B{Foliar Spray / Seed Treatment}
      B --> C[Plant Cell Uptake]
      C --> D{Modulate Stress Pathways}
      D --Enhanced Antioxidants, Root Growth--> E[Increased Crop Resilience]
  

Derivative 1.4: Cross-Domain Application (Marine Biotechnology: Antifouling Agents)

• Enabling Description: Halogenated psilocybin derivatives, particularly those with multiple heavy halogens (Br, I) at various indole positions, could be investigated as environmentally benign antifouling agents for marine coatings. The indole scaffold, common in natural products with diverse bioactivities, when heavily halogenated, can exhibit potent antimicrobial and deterrent properties against marine biofoulers (bacteria, diatoms, barnacles). The compounds would be incorporated into a biodegradable polymer matrix (e.g., PLA, PHA) for controlled release from ship hulls, aquaculture nets, or submerged sensors, preventing the attachment and growth of marine organisms.
• Mermaid Diagram:

  graph TD
      A[Poly-Halogenated Psilocybin Derivative] --> B{Biodegradable Polymer Matrix}
      B --> C[Marine Coating Application]
      C --Controlled Release--> D{Deter Biofoulers}
      D --> E[Reduced Biofouling]
  

Derivative 1.5: Cross-Domain Application (Materials Science: Self-Healing Polymers)

• Enabling Description: Halogenated psilocybin derivatives with specific functional groups (e.g., R3A/R3B are acyl groups that can undergo reversible covalent bonding, or R4 is a phosphate that can form supramolecular interactions) could be incorporated into polymer networks to impart self-healing properties. For example, a halogenated psilocybin derivative could act as a catalyst or cross-linking agent within a dynamic covalent network (e.g., Diels-Alder adducts, imine bonds). Upon damage, the halogenated derivative facilitates the re-formation of these bonds, restoring mechanical integrity. The halogenation might influence the electronic properties, enhancing catalytic activity or bond stability.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative (Functionalized)] --> B[Polymer Monomer / Precursor]
      B --> C[Polymerization with Cross-Linkers]
      C --> D[Self-Healing Polymer Network]
      D --Damage Event--> E[Re-formation of Bonds]
      E --> F[Restored Polymer Integrity]
  

Derivative 1.6: Integration with Emerging Tech (AI-Driven Synthesis Optimization)

• Enabling Description: The synthesis of novel halogenated psilocybin derivatives (e.g., compounds with complex halogenation patterns and diverse R3A/R3B groups) can be optimized using AI-driven retrosynthesis and reaction prediction algorithms. A machine learning model, trained on large datasets of chemical reactions and spectroscopic data, would predict optimal synthetic routes, reaction conditions (temperature, pressure, catalysts, solvents), and precursor selection for desired halogenated psilocybin derivatives. This includes predicting regioselectivity and yield for various halogenation methods (e.g., N-halosuccinimides, electrophilic halogenation, oxidative halogenation catalyzed by peroxidases). This AI-guided approach significantly accelerates the discovery and development of new derivatives.
• Mermaid Diagram:

  graph LR
      A[Desired Halogenated Psilocybin] --> B{AI Retrosynthesis Engine}
      B --> C[Predicted Precursors]
      B --> D[Predicted Reaction Conditions]
      C + D --> E[Automated Synthesis Platform]
      E --> F[Novel Halogenated Psilocybin]
      F --> G{Spectroscopic Analysis}
      G --> H[Data for AI Model Refinement]
  

Derivative 1.7: Integration with Emerging Tech (IoT Sensors for Real-time Pharmacokinetics)

• Enabling Description: Halogenated psilocybin derivatives (particularly those with radioisotopic halogens as in Derivative 1.1) can be monitored in vivo using implantable, miniaturized IoT-enabled biosensors. These sensors, potentially integrated into subcutaneous patches or ingestible capsules, would detect specific metabolic markers or the derivative itself (via micro-dialysis coupled to electrochemical detection or spectroscopic methods for radiolabeled compounds). Real-time data on concentration, metabolism, and bioavailability would be transmitted wirelessly to a cloud-based platform for personalized dosing adjustments and immediate efficacy assessment, especially for psychiatric disorder treatment where individual responses vary.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative] --> B[Patient Administration]
      B --> C[Implantable/Wearable IoT Biosensor]
      C --Real-time PK/PD Data--> D[Wireless Transmitter]
      D --> E[Cloud Platform]
      E --AI Analysis--> F[Personalized Dosing Regimen]
      F --> G[Healthcare Provider / Automated Dispenser]
  

Derivative 1.8: Integration with Emerging Tech (Blockchain for Supply Chain Integrity)

• Enabling Description: The manufacturing and distribution of pharmaceutical formulations containing halogenated psilocybin derivatives can be secured using a blockchain-based ledger. Each batch of raw materials, synthesized derivative, and finished pharmaceutical product would be assigned a unique cryptographic hash and recorded on an immutable distributed ledger. Smart contracts would automate compliance checks (e.g., purity assays, regulatory approvals, temperature control during transport), ensuring traceability from synthesis plant to patient. This prevents counterfeiting, ensures product authenticity, and enhances regulatory oversight, particularly critical for controlled substances like psilocybin derivatives.
• Mermaid Diagram:

  sequenceDiagram
      Actor A as Manufacturer
      Actor B as Distributor
      Actor C as Pharmacy
      Actor D as Patient
      A->>Blockchain: Register Raw Materials (Hash)
      A->>Blockchain: Register Halogenated Psilocybin Batch (Hash, Purity)
      A->>B: Ship Product
      B->>Blockchain: Record Shipment (Temperature, Location)
      B->>C: Deliver Product
      C->>Blockchain: Verify Authenticity (Scan QR/NFC)
      C->>D: Dispense Prescription
      D->>Blockchain: Confirm Receipt (Optional)
  

Derivative 1.9: The "Inverse" or Failure Mode (Low-Dose, Sub-Perceptual Modulators)

• Enabling Description: Develop halogenated psilocybin derivatives specifically optimized for extremely low-dose (microdosing) or sub-perceptual effects. This involves tuning halogenation patterns to achieve very high 5-HT2A receptor binding affinity but with rapid metabolism or altered downstream signaling pathways that minimize hallucinogenic potential. The goal is to maximize neuroplastic effects (e.g., enhanced mood, cognitive flexibility) while operating below the threshold for recreational or consciousness-altering experiences. These derivatives would be designed for "fail-safe" or "limited-functionality" in the sense that they intentionally do not produce intense psychoactive effects, simplifying clinical deployment and patient self-administration without supervision.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative (Low-Perceptual)] --> B[Microdosing Regimen]
      B --> C{Targeted Neuroplasticity}
      C --Minimal Hallucinogenic Effect--> D[Improved Mood/Cognition]
      D --No Supervised Setting Required--> E[Enhanced Patient Access]
  

Derivative 1.10: The "Inverse" or Failure Mode (Prodrugs with Inherent Deactivation Mechanism)

• Enabling Description: Design halogenated psilocybin prodrugs with an inherent "fail-safe" deactivation mechanism. For example, the prodrug moiety could be linked via a labile bond (e.g., a self-immolative linker) that, upon cleavage in vivo, releases the active halogenated psilocybin derivative and simultaneously initiates a rapid, non-enzymatic degradation pathway for the active compound itself. This ensures that the active compound has a very short therapeutic window or half-life, minimizing the risk of prolonged exposure, off-target effects, or abuse potential. The halogenation pattern could further influence the rate of this degradation.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Prodrug] --> B{In Vivo Activation}
      B --> C[Active Halogenated Psilocybin]
      B --> D[Self-Immolative Byproduct]
      C --Rapid Non-Enzymatic Degradation--> E[Inactive Metabolites]
      D --> F[Accelerated Clearance]
      style C fill:#f9f,stroke:#333,stroke-width:2px
  

Core Claim 22: Pharmaceutical or Recreational Drug Formulation

A pharmaceutical or recreational drug formulation comprising an effective amount of a chemical compound or salts thereof having the formula (I): [as defined in Claim 1], together with a pharmaceutically acceptable excipient, diluent or carrier.

Derivative 22.1: Material & Component Substitution (Biodegradable Microparticle Delivery System)

• Enabling Description: Instead of conventional excipients, the halogenated psilocybin derivative is encapsulated within biodegradable polymer microparticles (e.g., Poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), chitosan). These microparticles, typically ranging from 1-100 micrometers, allow for sustained or controlled release over days to weeks, reducing dosing frequency and improving patient compliance. The release kinetics can be tuned by varying polymer composition, molecular weight, and particle morphology. The microparticles would be formulated for parenteral injection (e.g., intramuscular or subcutaneous) or oral administration after enteric coating.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative] --> B[Encapsulation in PLGA/PCL Microparticles]
      B --> C[Injectable/Oral Formulation]
      C --> D{Controlled Release in vivo}
      D --Weeks/Days--> E[Sustained Therapeutic Levels]
  

Derivative 22.2: Operational Parameter Expansion (Transdermal Patch with Iontophoresis)

• Enabling Description: A transdermal patch system is developed for the halogenated psilocybin derivative, integrating iontophoresis for enhanced permeation. The patch consists of a drug reservoir containing the derivative (e.g., as a salt to facilitate ionic movement), an adhesive layer, and two electrodes connected to a miniature power source. A low-level electrical current is applied across the skin, driving the ionized drug molecules into the systemic circulation more efficiently than passive diffusion. This allows for precise control over delivery rate and avoids first-pass metabolism, especially beneficial for derivatives with poor oral bioavailability.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative (Ionized)] --> B[Drug Reservoir in Patch]
      B --> C[Transdermal Application]
      C --Iontophoresis (Electrical Current)--> D{Enhanced Skin Permeation}
      D --> E[Systemic Circulation]
      E --Controlled Delivery Rate--> F[Therapeutic Effect]
  

Derivative 22.3: Cross-Domain Application (Veterinary Medicine: Companion Animal Behavioral Disorders)

• Enabling Description: Pharmaceutical formulations of halogenated psilocybin derivatives are adapted for treating behavioral disorders in companion animals (e.g., severe anxiety, phobias, compulsive disorders in dogs and cats). The formulation would be an orally administered flavored chewable tablet or a transdermal gel, specifically tailored for animal physiology. Dosing would be weight-adjusted and the excipients would be palatable and non-toxic to the target species. The compounds would act as 5-HT2A receptor modulators to alleviate anxiety-related behaviors.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative] --> B[Flavored Chewable Tablet (Veterinary)]
      B --> C[Administration to Companion Animal]
      C --> D{5-HT2A Receptor Modulation}
      D --> E[Alleviated Behavioral Disorder]
  

Derivative 22.4: Cross-Domain Application (Forensic Science: Standard Reference Materials)

• Enabling Description: Highly purified (e.g., >99.9% by HPLC-MS, NMR) halogenated psilocybin derivatives are prepared as certified reference materials for forensic and analytical toxicology laboratories. These formulations, typically in precise concentrations in inert solvents (e.g., acetonitrile, methanol) or as lyophilized solids, are used for instrument calibration (GC-MS, LC-MS/MS), method validation, and quality control in drug testing and seizure analysis. The halogenation provides unique mass spectrometry fragmentation patterns, aiding in identification.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative] --> B[High Purity Synthesis]
      B --> C[Certified Reference Material (e.g., 1.0 mg/mL in MeOH)]
      C --> D{Forensic Labs / Analytical Toxicology}
      D --Instrument Calibration, Method Validation--> E[Accurate Drug Identification]
  

Derivative 22.5: Integration with Emerging Tech (3D-Printed Personalized Dosage Forms)

• Enabling Description: Pharmaceutical formulations are customized using 3D printing technology, allowing for personalized dosage forms of halogenated psilocybin derivatives. A powdered bed fusion or fused deposition modeling (FDM) printer fabricates tablets with precise drug loading, complex release profiles (e.g., multi-layer tablets for pulsatile release), and tailored shapes/sizes for individual patient needs (e.g., based on weight, metabolism, therapeutic response). The "ink" or powder would consist of the halogenated derivative blended with pharmaceutically acceptable polymers and excipients.
• Mermaid Diagram:

  graph TD
      A[Patient Data (Weight, Metabolism)] --> B[Prescription for Halogenated Psilocybin]
      B --> C[Digital Tablet Design (CAD)]
      C --> D[3D Pharmaceutical Printer]
      D --Customized Drug Loading, Release Profile--> E[Personalized Tablet]
      E --> F[Patient Administration]
  

Derivative 22.6: Integration with Emerging Tech (Augmented Reality for Administration Guidance)

• Enabling Description: Pharmaceutical formulations, particularly for complex administration routes (e.g., metered-dose inhalers for rapid onset, subcutaneous injections), are coupled with Augmented Reality (AR) applications. The AR app, running on a smartphone or smart glasses, overlays visual instructions and real-time feedback onto the physical drug product and patient's body, guiding the user through correct administration steps, ensuring proper technique, and confirming dose delivery. This enhances safety and efficacy for both medical and self-administered recreational contexts.
• Mermaid Diagram:

  sequenceDiagram
      Actor P as Patient
      Actor S as AR Smart Device
      P->>S: Launch AR App for Medication
      S->>P: Display 3D Instructions (Overlay on Physical Product)
      P->>P: Follow AR Guidance
      S->>P: Real-time Feedback (Correct angle, timing)
      P->>S: Confirm Administration
      S->>Blockchain: Log Successful Dose (Optional for controlled substances)
  

Derivative 22.7: The "Inverse" or Failure Mode (Taste-Masked, Abuse-Deterrent Formulations)

• Enabling Description: Develop taste-masked formulations of halogenated psilocybin derivatives (e.g., using microencapsulation with taste-masking polymers, inclusion complexes with cyclodextrins) to improve palatability for therapeutic use, while simultaneously incorporating abuse-deterrent properties. Abuse deterrence could involve physical barriers (e.g., crush-resistant matrices), chemical barriers (e.g., gelling agents when dissolved), or opioid antagonist combinations that are only active when the formulation is tampered with (e.g., crushed and injected). This ensures that while the intended oral therapeutic effect is maintained, methods of abuse are significantly hampered.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative] --> B[Taste-Masking Encapsulation]
      B --> C[Abuse-Deterrent Matrix (Physical/Chemical)]
      C --> D[Oral Tablet/Capsule]
      D --Intended Use--> E[Therapeutic Effect]
      D --Tampering Attempt (Crush, Dissolve)--> F[Deterrent Mechanism Activated (Gelling, Antagonist Release)]
      F --> G[Prevent Abuse]
  

Derivative 22.8: The "Inverse" or Failure Mode (Rapid Deactivation Excipient Co-Formulation)

• Enabling Description: Co-formulate the halogenated psilocybin derivative with an excipient that actively degrades or neutralizes the derivative upon exposure to specific environmental conditions outside the intended therapeutic route. For instance, a solid oral formulation could include an excipient (e.g., a strong oxidizing agent or a specific enzyme) that is activated upon crushing and dissolution in water, rapidly breaking down the halogenated psilocybin derivative. This serves as an overdose prevention or abuse deterrence mechanism, rendering large, extracted doses inactive. The excipient would be inert under normal storage and administration.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative] --> B[Co-Formulation with Deactivating Excipient]
      B --> C[Oral Dosage Form]
      C --Oral Administration (Intact)--> D[Therapeutic Effect]
      C --Crushed/Dissolved (Tampering)--> E[Excipient Activated]
      E --> F[Rapid Degradation of Derivative]
      F --> G[Prevent Overdose/Abuse]
  

Core Claim 23: Method for Treating a Psychiatric Disorder

A method for treating a psychiatric disorder, the method comprising administering to a subject in need thereof a pharmaceutical formulation comprising a chemical compound or salts thereof having the formula (I): [as defined in Claim 1], wherein the pharmaceutical formulation is administered in an effective amount to treat the psychiatric disorder in the subject.

Derivative 23.1: Material & Component Substitution (Gene Therapy Vectors for Endogenous Production)

• Enabling Description: Instead of administering the compound directly, a gene therapy approach is used. Viral vectors (e.g., AAV, lentivirus) are engineered to deliver nucleic acid sequences encoding the complete biosynthetic pathway for a specific halogenated psilocybin derivative (including halogenase enzymes) directly into target neuronal cells or glial cells in the brain. This allows for sustained, localized, and on-demand endogenous production of the therapeutic compound within the brain, bypassing systemic administration and metabolism, and achieving highly precise drug delivery for psychiatric disorders.
• Mermaid Diagram:

  graph TD
      A[Nucleic Acids (Biosynthetic Pathway + Halogenase)] --> B[AAV/Lentivirus Vector]
      B --> C[Stereotaxic Brain Injection]
      C --> D{Neuronal/Glial Cell Transduction}
      D --> E[Endogenous Production of Halogenated Psilocybin]
      E --> F[Localized Therapeutic Effect for Psychiatric Disorder]
  

Derivative 23.2: Operational Parameter Expansion (Ultra-Low Dose, Chronic Microdosing Regimen)

• Enabling Description: The method of treatment involves administering ultra-low, sub-perceptual doses (e.g., 1/100th to 1/1000th of a typical therapeutic dose, in picograms or low nanograms per kilogram body weight) of the halogenated psilocybin derivative on a chronic, daily or every-other-day basis for months or years. This regimen aims to induce subtle, persistent neuroadaptive changes (e.g., subtle increases in neurotrophic factors, mild modulation of receptor sensitivity) without acute psychoactive effects, for conditions like chronic anxiety, mild depression, or neurodegenerative disorders where sustained neuroplasticity is beneficial. The derivative would be chosen for favorable pharmacokinetics at these low doses.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative] --> B[Ultra-Low Dose Formulation]
      B --> C[Chronic (Daily/EOD) Administration]
      C --Months/Years--> D{Sustained Neuroadaptive Changes}
      D --> E[Long-term Symptom Amelioration (Sub-Perceptual)]
  

Derivative 23.3: Cross-Domain Application (Neuromodulation for Chronic Pain Management)

• Enabling Description: The halogenated psilocybin derivative is administered as an adjunct therapy in chronic neuropathic pain management, leveraging its 5-HT2A receptor modulation to address the psychological and affective components of pain. Administered via a patient-controlled analgesic (PCA) pump (subcutaneously or epidurally) at sub-hallucinogenic doses, the compound modulates descending serotonergic pain inhibitory pathways and addresses comorbid anxiety/depression often associated with chronic pain, improving overall pain perception and quality of life.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative] --> B[PCA Pump (Sub-Hallucinogenic Dose)]
      B --> C[Modulate Descending Pain Pathways / Affective Pain]
      C --> D[Reduced Chronic Neuropathic Pain Perception]
      C --> E[Improved Mood/Anxiety]
  

Derivative 23.4: Cross-Domain Application (Rehabilitation Medicine: Post-Stroke Cognitive Recovery)

• Enabling Description: Halogenated psilocybin derivatives are used in a controlled clinical setting to enhance neurorehabilitation following ischemic stroke, specifically to facilitate cognitive recovery (e.g., speech, motor learning, executive function). Administered during a critical plasticity window post-stroke, the 5-HT2A modulation (potentially combined with structured therapy sessions) aims to boost synaptogenesis and dendritic branching in peri-infarct areas, accelerating the brain's ability to reorganize and recover lost functions. Dosage and timing would be carefully controlled to optimize plasticity without adverse psychoactive effects.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative] --> B[Controlled Administration (Post-Stroke)]
      B --> C[Enhance Synaptogenesis/Dendritic Branching]
      C --> D[Intensive Cognitive/Motor Therapy]
      D --> E[Accelerated Post-Stroke Cognitive Recovery]
  

Derivative 23.5: Integration with Emerging Tech (Closed-Loop Biofeedback System for Dosing)

• Enabling Description: Treatment involves a closed-loop biofeedback system that continuously monitors physiological markers (e.g., EEG brainwave patterns, heart rate variability, skin conductance) indicative of a patient's psychiatric state and response to the halogenated psilocybin derivative. An AI algorithm analyzes these data in real-time and dynamically adjusts the dose or delivery rate of the compound (e.g., via a smart intravenous pump or transdermal patch), ensuring optimal therapeutic effect while minimizing side effects and over-dosing. The system learns individual patient responses over time for precision medicine.
• Mermaid Diagram:

  graph TD
      A[Patient] --> B[Physiological Sensors (EEG, HRV)]
      B --> C[Data Acquisition Unit]
      C --> D{AI Dosing Algorithm}
      D --Real-time Dose Adjustment--> E[Automated Drug Delivery Device]
      E --> A
      D --Monitor Therapeutic Efficacy--> F[Psychiatric Disorder Treatment]
  

Derivative 23.6: The "Inverse" or Failure Mode (Non-Hallucinogenic, Receptor-Selective Agonists for Depression)

• Enabling Description: The halogenated psilocybin derivatives are specifically designed to be non-hallucinogenic, but still effective in treating depression. This is achieved through targeted halogenation patterns that confer selective agonism on certain downstream signaling pathways of the 5-HT2A receptor (e.g., Gq protein coupling, β-arrestin recruitment) while disfavoring others associated with hallucinogenesis. This "biased agonism" allows for the therapeutic benefits of neuroplasticity and mood elevation without the psychedelic experience, enabling broader clinical use and patient acceptance.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative (Biased Agonist)] --> B[5-HT2A Receptor]
      B --Selective Gq/beta-arrestin Coupling--> C[Neuroplastic Signaling Pathway]
      C --No Hallucinogenic Pathway--> D[Antidepressant Effect]
      D --> E[Treat Depression (Non-Hallucinogenic)]
  

Core Claim 26: Method of Making (Halogenated Precursor)

A method of making a halogenated psilocybin derivative, the method comprising contacting a host cell comprising a psilocybin biosynthetic enzyme complement with a halogenated psilocybin precursor compound, wherein the host cell produces the halogenated psilocybin derivative.

Derivative 26.1: Material & Component Substitution (Synthetic Halogenated Amino Acid Feedstock)

• Enabling Description: Instead of relying on simpler halogenated precursors, the method utilizes synthetically produced, stereospecifically enriched halogenated L-tryptophan or L-4-hydroxytryptophan as the starting material. For instance, L-7-fluoro-tryptophan or L-5-bromo-4-hydroxytryptophan can be chemically synthesized with high enantiomeric purity. This "designer feedstock" is then supplied to the host cell engineered with the psilocybin biosynthetic enzymes (e.g., PsiD, PsiK, PsiM, PsiH, TrpB), ensuring the resulting halogenated psilocybin derivative maintains the desired stereochemistry and regiochemical halogenation pattern without requiring a host cell-derived halogenase. This simplifies the metabolic engineering required in the host cell.
• Mermaid Diagram:

  graph TD
      A[Stereospecific Halogenated L-Tryptophan] --> B[Host Cell (Psilocybin Biosynthetic Enzymes)]
      B --> C[Halogenated Psilocybin Derivative]
      C --High Stereopurity--> D[Purification]
  

Derivative 26.2: Operational Parameter Expansion (Continuous Flow Bioreactor with Cascade Enzymes)

• Enabling Description: The bioproduction is conducted in a continuous flow bioreactor system, where the host cells (e.g., Saccharomyces cerevisiae or E. coli) expressing the psilocybin biosynthetic enzyme complement are immobilized in a packed bed or hollow fiber module. A halogenated psilocybin precursor compound is continuously fed into the bioreactor. The enzymes in the immobilized cells convert the precursor to the derivative, which is then continuously harvested from the effluent. This system allows for higher volumetric productivity, tighter process control, and easier integration with downstream purification, operating at optimized flow rates, temperatures, and nutrient concentrations for maximum yield.
• Mermaid Diagram:

  graph LR
      A[Halogenated Precursor Feed] --> B[Continuous Flow Bioreactor (Immobilized Cells)]
      B --Enzymatic Conversion--> C[Effluent (Halogenated Psilocybin Derivative)]
      C --> D[Downstream Purification]
      D --> E[Finished Product]
  

Derivative 26.3: Integration with Emerging Tech (Optogenetic Control of Biosynthetic Pathway)

• Enabling Description: The expression of key psilocybin biosynthetic enzymes within the host cell is controlled using optogenetics. Light-sensitive promoters are engineered upstream of the genes encoding enzymes like PsiK or PsiM. By exposing the host cell culture to specific wavelengths and intensities of light, the production rate of the halogenated psilocybin derivative can be precisely modulated in real-time. This allows for fine-tuning of metabolic flux, preventing accumulation of toxic intermediates, or inducing production only when desired, leading to improved yields and purity.
• Mermaid Diagram:

  graph TD
      A[Host Cell (Optogenetically Controlled Enzymes)] --> B{Light Stimulation (Specific Wavelength/Intensity)}
      B --> C[Activate Gene Expression (e.g., PsiK, PsiM)]
      C --> D[Biosynthesis of Halogenated Psilocybin]
      D --Modulated Rate--> E[Derivative Production]
  

Derivative 26.4: The "Inverse" or Failure Mode (Engineered Metabolite Sink for Excess Precursor)

• Enabling Description: To prevent accumulation of potentially toxic halogenated psilocybin precursor compounds or to manage overflow metabolism, the host cell is engineered with a "metabolite sink" pathway. This pathway rapidly converts excess halogenated precursor (or an early intermediate) into a benign, easily excretable, or valorizable byproduct (e.g., a non-psychoactive sugar conjugate, a stable amino acid). This acts as a fail-safe, diverting metabolic flow when the primary biosynthetic pathway for the derivative is saturated or bottlenecked, ensuring host cell viability and preventing undesirable side-product formation.
• Mermaid Diagram:

  graph TD
      A[Halogenated Precursor Compound] --> B[Host Cell]
      B --Primary Pathway--> C[Halogenated Psilocybin Derivative]
      B --Excess Precursor (Metabolic Overflow)--> D[Metabolite Sink Pathway]
      D --> E[Benign Byproduct (Excreted/Stored)]
      style D fill:#f9f,stroke:#333,stroke-width:2px
  

Core Claim 35: Method of Making (Halogenase-Mediated Halogenation)

A method of making a halogenated psilocybin derivative, the method comprising contacting a host cell with a non-halogenated psilocybin precursor compound and a halogen, the host cell further comprising a halogenase capable of halogenating the non-halogenated psilocybin compound and forming the halogenated psilocybin precursor compound.

Derivative 35.1: Material & Component Substitution (Directed Evolution of Halogenase Enzymes)

• Enabling Description: The halogenase enzyme within the host cell is not a wild-type enzyme but a variant generated through directed evolution. High-throughput screening (e.g., using reporter assays for halogenation activity) is employed to select for halogenase mutants with improved activity (e.g., higher turnover rate, increased regioselectivity, broader substrate scope to new halogenation sites or types of halogens), or enhanced stability under bioprocess conditions. This optimizes the in situ halogenation step, leading to higher yields and purer halogenated psilocybin derivatives from non-halogenated precursors.
• Mermaid Diagram:

  graph TD
      A[Wild-Type Halogenase Gene] --> B[Random Mutagenesis]
      B --> C[Halogenase Variant Library]
      C --> D{High-Throughput Screening (Regioselectivity, Activity)}
      D --> E[Improved Halogenase Variant]
      E --> F[Host Cell (Engineered with Improved Halogenase)]
      F --> G[Non-Halogenated Precursor + Halogen Source]
      G --> H[Halogenated Psilocybin Derivative]
  

Derivative 35.2: Operational Parameter Expansion (Microfluidic Bioreactors for Halogenation Control)

• Enabling Description: The halogenase-mediated halogenation step is performed in a microfluidic bioreactor. Host cells expressing the halogenase, along with the non-halogenated psilocybin precursor and the halogen source (e.g., a halide salt and a peroxide for oxidative halogenases), are continuously flowed through microchannels. The precise control over reaction parameters (e.g., mixing ratios, residence time, temperature gradients) at the microscale allows for fine-tuning of the halogenation reaction, optimizing regioselectivity and minimizing over-halogenation or undesirable side reactions. Real-time optical sensing within the channels can monitor reaction progress.
• Mermaid Diagram:

  graph LR
      A[Non-Halogenated Precursor] --> M[Microfluidic Mixing Chamber]
      B[Halogen Source] --> M
      C[Host Cells (Halogenase)] --> M
      M --> D[Microreactor Channel]
      D --Controlled Reaction Conditions--> E[Halogenated Precursor Compound]
      E --> F[Downstream Biosynthesis (Psilocybin Enzymes)]
  

Derivative 35.3: Integration with Emerging Tech (CRISPR-Mediated Halogenase Integration & Regulation)

• Enabling Description: CRISPR/Cas9 gene editing technology is used to precisely integrate and regulate the expression of the halogenase gene into the host cell genome. This ensures stable, high-level expression of the halogenase at a specific genomic locus, avoiding issues with plasmid instability or copy number variation. Furthermore, CRISPR interference (CRISPRi) or activation (CRISPRa) systems can be employed to finely tune the halogenase expression in response to environmental cues or specific induction protocols, optimizing the halogenation step in the overall biosynthetic pathway for halogenated psilocybin derivatives.
• Mermaid Diagram:

  graph TD
      A[Halogenase Gene] --> B[CRISPR/Cas9 Genome Integration]
      C[Regulatory Elements (Promoters)] --> D[CRISPRi/a for Gene Regulation]
      B + D --> E[Engineered Host Cell (Stable, Regulated Halogenase)]
      E --> F[Non-Halogenated Precursor + Halogen Source]
      F --> G[Halogenated Psilocybin Derivative]
  

Derivative 35.4: The "Inverse" or Failure Mode (Engineered De-Halogenase for Detoxification)

• Enabling Description: To manage potential toxicity from accumulated halogenated intermediates or to provide a "safety switch" in the bioproduction process, the host cell is engineered to express a de-halogenase enzyme. This de-halogenase would specifically remove halogen atoms from unintended byproducts or from the halogenated psilocybin derivative itself if, for example, the derivative proved toxic to the cell at high concentrations. This acts as a detoxification pathway, ensuring host cell viability and preventing environmental release of persistent halogenated compounds in case of process failure.
• Mermaid Diagram:

  graph TD
      A[Non-Halogenated Precursor + Halogen] --> B[Host Cell (Halogenase)]
      B --> C[Halogenated Precursor / Derivative]
      B --Excess Halogenated Compounds / Off-Target--> D[De-Halogenase Pathway]
      D --> E[De-Halogenated, Less Toxic Byproducts]
      style D fill:#f9f,stroke:#333,stroke-width:2px
  

Core Claim 44: Method for Modulating a 5-HT2A Receptor

A method for modulating a 5-HT2A receptor, the method comprising contacting a 5-HT2A receptor with a chemical compound or salts thereof having the formula (I): [as defined in Claim 1] under reaction conditions sufficient to thereby modulate receptor activity.

Derivative 44.1: Material & Component Substitution (Non-Tryptamine Scaffolds with Halogenation)

• Enabling Description: Instead of a psilocybin derivative (tryptamine backbone), the 5-HT2A receptor modulation is achieved using halogenated derivatives of other known 5-HT2A agonists or antagonists (e.g., phenethylamines, ergolines, or novel synthetic scaffolds) where the halogenation is crucial for receptor affinity, selectivity, or biased agonism. For instance, a halogenated derivative of DOI (2,5-dimethoxy-4-iodoamphetamine) or a similarly structured halogenated phenethylamine could be used. The halogen (e.g., F, Cl, Br, I) would be strategically placed on the aromatic ring to optimize binding and signaling bias at the 5-HT2A receptor.
• Mermaid Diagram:

  graph TD
      A[Non-Tryptamine Scaffold (e.g., Phenethylamine)] --> B[Halogenation]
      B --> C[Halogenated Non-Tryptamine Modulator]
      C --> D{Contact 5-HT2A Receptor}
      D --> E[Modulate Receptor Activity (Agonism/Antagonism)]
  

Derivative 44.2: Operational Parameter Expansion (Cryogenic Receptor-Ligand Binding Assays)

• Enabling Description: The method for modulating a 5-HT2A receptor is performed under cryogenic conditions (e.g., 77K-200K) using techniques like cryo-electron microscopy (cryo-EM) or ligand binding assays at low temperatures. This allows for the capture and analysis of transient receptor-ligand complexes (between the 5-HT2A receptor and the halogenated psilocybin derivative) that are unstable at physiological temperatures. Studying these complexes at extreme low temperatures provides atomic-level detail on binding modes, conformational changes, and the role of specific halogen-receptor interactions, enabling more rational drug design.
• Mermaid Diagram:

  graph TD
      A[5-HT2A Receptor] --> B[Halogenated Psilocybin Derivative]
      B --> C[Co-incubation at Cryogenic Temp]
      C --> D{Cryo-EM / Cryo-Binding Assay}
      D --> E[Atomic-level Binding Mechanism / Receptor Conformation]
      E --> F[Rational Drug Design]
  

Derivative 44.3: Cross-Domain Application (Biosensor Development for Environmental Toxin Detection)

• Enabling Description: The 5-HT2A receptor, potentially modified to increase stability, is integrated into a biosensor platform for detecting halogenated environmental toxins that mimic serotonergic compounds (e.g., certain pesticides, industrial pollutants). The halogenated psilocybin derivative acts as a known internal control or competitor ligand. The biosensor would use surface plasmon resonance (SPR) or fluorescence resonance energy transfer (FRET) to measure changes in ligand binding or receptor activation in response to environmental samples, indicating the presence and concentration of toxins.
• Mermaid Diagram:

  graph TD
      A[Modified 5-HT2A Receptor (Biosensor)] --> B[Flow Cell / Microfluidic Channel]
      C[Environmental Sample (Potential Toxin)] --> B
      D[Halogenated Psilocybin (Control Ligand)] --> B
      B --> E{SPR / FRET Detection}
      E --Ligand Binding Changes--> F[Identify/Quantify Halogenated Environmental Toxins]
  

Derivative 44.4: Integration with Emerging Tech (Organ-on-a-Chip for Receptor Profiling)

• Enabling Description: The method utilizes 5-HT2A receptors expressed in human neuronal cells within an "organ-on-a-chip" microfluidic device. This device precisely mimics the in vivo microenvironment of brain tissue, including cell types, extracellular matrix, and fluid flow. Halogenated psilocybin derivatives are introduced to the chip, and their effects on 5-HT2A receptor activity, downstream signaling, and network electrophysiology are monitored in real-time. This provides a more physiologically relevant and high-throughput platform for receptor profiling and drug screening than traditional 2D cell cultures.
• Mermaid Diagram:

  graph TD
      A[Human Neuronal Cells (5-HT2A Expressing)] --> B[Organ-on-a-Chip Device]
      C[Halogenated Psilocybin Derivative] --> B
      B --Microfluidic Perfusion--> D{Real-time Monitoring (Electrophysiology, Signaling)}
      D --> E[Detailed 5-HT2A Receptor Activity Profile]
      E --> F[Improved Drug Candidate Selection]
  

Derivative 44.5: The "Inverse" or Failure Mode (Competitive Antagonism for Overdose Reversal)

• Enabling Description: The halogenated psilocybin derivative is specifically designed to act as a potent and selective competitive antagonist of the 5-HT2A receptor, with high binding affinity but zero efficacy. This "inverse" application is for the rapid reversal of acute hallucinogenic effects or overdose from other 5-HT2A agonists (e.g., classical psychedelics, certain recreational drugs). Administered intravenously, this derivative quickly outcompetes agonists at the receptor site, restoring normal serotonergic signaling and mitigating adverse psychoactive events. The halogenation pattern would be optimized for high affinity and brain penetrance.
• Mermaid Diagram:

  graph TD
      A[5-HT2A Agonist (Overdose/Hallucination)] --> B[5-HT2A Receptor]
      C[Halogenated Psilocybin Derivative (Competitive Antagonist)] --> B
      B --Antagonist Binds Preferentially--> D[Block Agonist Effect]
      D --> E[Reverse Hallucinogenic Effects / Overdose]
      style C fill:#f9f,stroke:#333,stroke-width:2px
  

Core Claim 47: Use in Manufacture of Pharmaceutical or Recreational Drug Formulation

A use of a chemical compound or salts thereof having the formula (I): [as defined in Claim 1] in the manufacture of a pharmaceutical or recreational drug formulation.

Derivative 47.1: Material & Component Substitution (Biopolymer Scaffolds for Drug Implants)

• Enabling Description: The halogenated psilocybin derivative is manufactured into drug implants using biocompatible and biodegradable biopolymers (e.g., poly(lactic-co-glycolic acid) (PLGA), polydioxanone (PDO), hyaluronic acid hydrogels). The derivative is homogeneously dispersed or encapsulated within the polymer matrix. These implants are manufactured via extrusion, injection molding, or 3D printing, creating devices (e.g., subcutaneous rods, intracerebral microspheres) that provide sustained release of the drug over extended periods (months to years), thus reducing dosing frequency for chronic psychiatric conditions.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative] --> B[Biocompatible Biopolymer]
      B --> C[Extrusion / 3D Printing]
      C --> D[Drug Implant (e.g., Subcutaneous Rod)]
      D --> E[Sustained Release in vivo]
      E --> F[Therapeutic Effect]
  

Derivative 47.2: Operational Parameter Expansion (High-Throughput Robotic Compounding)

• Enabling Description: The manufacture of pharmaceutical formulations is performed using fully automated, high-throughput robotic compounding systems. These systems precisely weigh and mix the halogenated psilocybin derivative with various excipients, diluents, and carriers in small batch sizes, under tightly controlled environmental conditions (e.g., humidity, temperature, inert atmosphere). This enables rapid prototyping of new formulations, optimization of excipient ratios, and agile production of personalized medicines or small clinical trial batches, minimizing human error and maximizing efficiency.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative (Bulk)] --> B[Automated Dispensing Robot]
      C[Excipients/Diluents (Bulk)] --> B
      B --> D[Robotic Mixing Station]
      D --Controlled Environment--> E[Formulation Batch (e.g., Capsules, Liquid)]
      E --> F[Quality Control (Automated)]
      F --> G[Packaging]
  

Derivative 47.3: Cross-Domain Application (Nutraceutical Industry: Cognitive Enhancement Supplements)

• Enabling Description: The halogenated psilocybin derivative is manufactured into nutraceutical formulations, intended for cognitive enhancement or mood support in healthy individuals (at microdoses or sub-perceptual levels, depending on regulatory frameworks). These formulations could include capsules, powders for blending into beverages, or functional foods (e.g., protein bars, gummies). The manufacturing process would focus on high bioavailability, taste masking, and stability within a food matrix, using food-grade excipients and processing techniques.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative (Microdose)] --> B[Food-Grade Excipients]
      B --> C[Manufacturing Process (e.g., Encapsulation, Blending)]
      C --> D[Nutraceutical Product (e.g., Cognitive Supplement)]
      D --> E[Consumer (Cognitive Enhancement)]
  

Derivative 47.4: Integration with Emerging Tech (AI-Driven Formulation Development)

• Enabling Description: The selection of excipients and optimal formulation parameters for halogenated psilocybin derivatives is driven by AI and computational modeling. Machine learning algorithms, trained on vast datasets of drug-excipient interactions, stability data, and bioavailability profiles, predict the ideal formulation composition for desired physicochemical properties (e.g., solubility, dissolution rate, long-term stability) and pharmacokinetic performance in vivo. This accelerates the formulation development cycle, identifies synergistic excipient combinations, and minimizes experimental iterations.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative Data] --> B[AI Formulation Engine]
      C[Excipient Database] --> B
      D[Desired Formulation Properties] --> B
      B --> E[Predicted Optimal Formulation Composition]
      E --> F[Automated Manufacturing]
      F --> G[Validation Testing]
      G --> H[Data for AI Model Refinement]
  

Derivative 47.5: The "Inverse" or Failure Mode (Manufacturing Process for Placebo-Controlled Trial Kits)

• Enabling Description: The manufacturing process is specifically designed to produce identical-looking and tasting placebo formulations alongside the active halogenated psilocybin derivative formulations for blinded clinical trials. This involves using inert excipients to mimic the physical properties (color, texture, weight, dissolution) and taste of the active drug product. The manufacturing workflow includes strict segregation and labeling protocols to ensure blinding integrity for placebo-controlled studies, which are crucial for evaluating the efficacy of psychoactive compounds.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative] --> B[Active Formulation Line]
      C[Inert Excipients] --> D[Placebo Formulation Line]
      B --> E[Final Product (Active)]
      D --> F[Final Product (Placebo)]
      E + F --> G[Blind Labeling & Packaging]
      G --> H[Clinical Trial Kits]
      style D fill:#f9f,stroke:#333,stroke-width:2px
  

Core Claim 50: Use as a Pharmaceutical or Recreational Drug Formulation

A use of a chemical compound or salts thereof having the formula (I): [as defined in Claim 1] together with a diluent, carrier or excipient, as a pharmaceutical or recreational drug formulation.

Derivative 50.1: Material & Component Substitution (Edible Films for Oromucosal Delivery)

• Enabling Description: The halogenated psilocybin derivative is formulated into ultrathin, edible oral films composed of rapidly dissolving biopolymers (e.g., pullulan, HPMC, PVA). These films are designed for oromucosal administration (buccal or sublingual), allowing for rapid absorption directly into the bloodstream, bypassing first-pass metabolism and providing a quicker onset of action compared to traditional oral tablets. The film matrix provides taste masking and can be easily administered without water.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative] --> B[Biopolymer Solution]
      B --> C[Film Casting / Drying]
      C --> D[Edible Oromucosal Film]
      D --Buccal/Sublingual Absorption--> E[Rapid Systemic Delivery]
      E --> F[Quick Onset of Therapeutic Effect]
  

Derivative 50.2: Operational Parameter Expansion (Metered-Dose Inhaler (MDI) for Pulmonary Delivery)

• Enabling Description: The halogenated psilocybin derivative is formulated for pulmonary delivery via a metered-dose inhaler (MDI). The derivative is micronized (e.g., particle size 1-5 µm) and suspended or dissolved in a propellant (e.g., HFA). This method provides very rapid onset of action, direct delivery to the central nervous system (via nose-to-brain pathways or systemic absorption through the highly vascularized lungs), and avoids first-pass metabolism. Precise dosing is achieved with each actuation of the MDI.
• Mermaid Diagram:

  graph TD
      A[Micronized Halogenated Psilocybin Derivative] --> B[Propellant]
      B --> C[Metered-Dose Inhaler]
      C --Pulmonary Administration--> D[Rapid Absorption (Lungs/Brain)]
      D --> E[Fast Onset Therapeutic Effect]
  

Derivative 50.3: Cross-Domain Application (Cosmeceuticals: Transdermal Neurotransmitter Modulation for Skin Conditions)

• Enabling Description: Halogenated psilocybin derivatives (at very low, non-systemic doses) are incorporated into cosmeceutical formulations (e.g., creams, serums, patches) for topical application to treat neuro-inflammatory skin conditions (e.g., eczema, psoriasis, rosacea). The hypothesis is that local 5-HT2A receptor modulation on skin cells (keratinocytes, melanocytes, immune cells) or nerve endings can reduce inflammation, modulate immune responses, and alleviate pruritus or pain directly at the site of application without systemic psychoactive effects.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative (Low Dose)] --> B[Cosmeceutical Carrier (Cream/Serum)]
      B --> C[Topical Skin Application]
      C --> D{Local 5-HT2A Receptor Modulation (Skin)}
      D --Reduced Inflammation, Pruritus--> E[Improved Skin Condition]
  

Derivative 50.4: Integration with Emerging Tech (AI-Personalized Recreational Experiences)

• Enabling Description: For recreational drug formulations, AI algorithms analyze user-provided data (e.g., desired intensity, mood, past experiences, biometric data from wearables) to recommend personalized halogenated psilocybin derivative formulations and dosing regimens. The AI could suggest specific derivatives (e.g., 4-chloro-psilocybin vs. 7-bromo-psilocybin, each with subtly different subjective effects), optimal carriers for desired onset/duration, and environmental settings, providing a tailored and potentially safer recreational experience.
• Mermaid Diagram:

  graph TD
      A[User Preferences (Mood, Intensity)] --> B[Wearable Biometric Data]
      C[AI Recommendation Engine] --> D[Personalized Halogenated Psilocybin Formulation/Dose]
      D --> E[Recreational User]
      C --Suggest Environmental Setting--> E
  

Derivative 50.5: The "Inverse" or Failure Mode (Non-Psychoactive "Control" Compounds for Research)

• Enabling Description: Formulations of halogenated psilocybin derivatives are intentionally designed to be non-psychoactive and serve as active control compounds in human research. This could involve modifications (e.g., additional bulky substituents on the nitrogen, or specific halogenation patterns that significantly reduce brain penetrance or 5-HT2A affinity/efficacy) that render them inert in terms of psychoactive effects while maintaining a similar chemical structure to the active drug. This allows for rigorous double-blind, active-controlled studies in psychiatric research, providing a more robust placebo than an inert substance.
• Mermaid Diagram:

  graph TD
      A[Halogenated Psilocybin Derivative (Active)] --> B[Research Study (Experimental Group)]
      C[Halogenated Psilocybin Derivative (Non-Psychoactive Control)] --> D[Research Study (Control Group)]
      B --> E[Measure Therapeutic Efficacy]
      D --> F[Establish Active Control Baseline]
      style C fill:#f9f,stroke:#333,stroke-width:2px
  

---

Combination Prior Art Scenarios

Here are at least 3 "Combination Prior Art" scenarios where the US Patent 12138276 could be combined with existing open-source standards to create obvious disclosures.

Scenario 1: Halogenated Psilocybin Production using Open-Source Synthetic Biology Toolkit (e.g., BioBricks)

• Prior Art Context: US12138276 claims methods of making halogenated psilocybin derivatives using host cells with psilocybin biosynthetic enzyme complements and/or halogenases (Claims 26, 35). The advent of synthetic biology and open-source toolkits like BioBricks (from the iGEM Foundation) has standardized the design and assembly of genetic circuits for metabolic engineering.

• Combination Disclosure: A method for producing a halogenated psilocybin derivative by constructing a genetic circuit using BioBricks standard parts. This circuit would comprise nucleic acid sequences encoding the PsiD, PsiH, PsiK, PsiM enzymes (from the natural psilocybin pathway) and a suitable halogenase enzyme (e.g., from an open-source enzyme database or a published sequence like those in the patent). These BioBricks would be assembled and transformed into a standard, open-source microbial host (e.g., E. coli strain K-12, Saccharomyces cerevisiae strain S288C) available through public repositories. The host cell is then cultured in a standard growth medium containing appropriate non-halogenated psilocybin precursors (e.g., tryptophan or 4-hydroxytryptophan) and a halide salt (e.g., KBr, NaCl) for the halogenase activity. The halogenated psilocybin derivative is subsequently isolated using standard biochemical purification techniques. The use of an open-source genetic engineering framework and publicly available host strains makes the implementation of the claimed biosynthetic methods obvious.

• Mermaid Diagram:

  graph TD
      A[PsiD BioBrick] --> B[Genetic Circuit Assembly (iGEM Standard)]
      C[PsiH BioBrick] --> B
      D[PsiK BioBrick] --> B
      E[PsiM BioBrick] --> B
      F[Halogenase BioBrick] --> B
      B --> G[Transformation into Open-Source E. coli/Yeast]
      G --> H[Culture with Precursor + Halide]
      H --> I[Halogenated Psilocybin Derivative Production]
      I --> J[Standard Purification]
  

Scenario 2: Blockchain-Enabled Traceability for Halogenated Psilocybin Pharmaceutical Supply Chain (e.g., Hyperledger Fabric)

• Prior Art Context: US12138276 claims pharmaceutical and recreational drug formulations comprising halogenated psilocybin derivatives (Claims 22, 50) and their use in manufacture (Claim 47). Blockchain technology, particularly open-source enterprise-grade platforms like Hyperledger Fabric, is widely recognized for enhancing supply chain transparency and integrity, especially for pharmaceuticals.

• Combination Disclosure: A system for ensuring the authenticity and traceability of pharmaceutical formulations containing halogenated psilocybin derivatives using a Hyperledger Fabric blockchain network. Each participant in the supply chain (manufacturer, distributor, pharmacy) operates a peer node on the network. Smart contracts are deployed to record immutable transactions, including the origin of raw materials, manufacturing batch details (including halogenated derivative synthesis and purity reports), temperature and humidity logs during transport (integrated via IoT sensors, see Derivative 1.7), and dispensing events to patients. Each product unit (e.g., bottle, blister pack) of the halogenated psilocybin formulation is serialized with a unique identifier (e.g., QR code) linked to its blockchain record, allowing consumers and regulators to verify authenticity and track its journey from production to administration. This public, verifiable ledger renders any future attempts to claim novel supply chain tracking for these compounds obvious.

• Mermaid Diagram:

  sequenceDiagram
      participant M as Manufacturer (Hyperledger Node)
      participant D as Distributor (Hyperledger Node)
      participant P as Pharmacy (Hyperledger Node)
      participant R as Regulator (Auditor Node)
      M->>M: Synthesize Halogenated Psilocybin
      M->>M: Formulate Drug
      M->>M: Assign Unique Serial ID (QR)
      M->>Blockchain: Invoke Smart Contract (Record Product Batch, Serial, Purity)
      M->>D: Ship Product (Serial ID)
      D->>Blockchain: Invoke Smart Contract (Record Shipment, IoT Data)
      D->>P: Deliver Product
      P->>Blockchain: Invoke Smart Contract (Verify Product, Record Receipt)
      P->>P: Dispense to Patient
      R->>Blockchain: Query Ledger (Audit Trail)
  

Scenario 3: AI-Driven Optimization of Halogenated Psilocybin Clinical Dosing (e.g., Open-Source Machine Learning Libraries like TensorFlow/PyTorch)

• Prior Art Context: US12138276 claims methods of treating psychiatric disorders by administering an effective amount of a halogenated psilocybin derivative (Claim 23) and refers to the need for tailored dosing based on patient characteristics. The widespread availability of open-source machine learning libraries like TensorFlow and PyTorch makes AI-driven personalized medicine implementations accessible.

• Combination Disclosure: A method for optimizing the effective dose of a halogenated psilocybin derivative for treating a psychiatric disorder in a subject using an AI model built with open-source machine learning libraries (e.g., TensorFlow or PyTorch). Clinical data (patient demographics, genetic markers, physiological responses like EEG/fMRI, symptom severity scores, historical treatment responses to various doses of halogenated psilocybin derivatives) from a large, de-identified patient cohort is used to train a recurrent neural network (RNN) or transformer model. This AI model learns to predict individual patient responses and optimal dosing regimens for specific halogenated psilocybin derivatives. For a new patient, their baseline data is fed into the trained model, which then recommends a personalized starting dose and titration schedule. Subsequent monitoring (e.g., via IoT sensors, see Derivative 1.7) provides feedback to the model for continuous refinement of the dosing strategy.

• Mermaid Diagram:

  graph TD
      A[De-identified Patient Clinical Data] --> B[AI Model Training (TensorFlow/PyTorch)]
      B --> C[Trained AI Dosing Model]
      D[New Patient Baseline Data] --> C
      C --> E[Predicted Optimal Halogenated Psilocybin Dose/Regimen]
      E --> F[Patient Administration]
      F --> G[Real-time Response Data (IoT/Clinical)]
      G --> C